The biology of estrogen-induced apoptosis has created a need for therapeutic approaches to block cell survival pathways in order to augment hormone-induced apoptosis and to provide an inexpensive targeted therapy to maintain ER-positive BC patients indefinitely. Here, ESR1 is linked to breast cancer.